Pharma Biden looks to Germany for answers on how to tackle high U.S. drug prices: analyst

With the U.S. election just two weeks away, Democratic presidential nominee Joe Biden is offering clues about how his administration would approach drug pricing—and he's looking to Germany.

Under Biden’s plan, the government would set up a group to assess “fair” values of drugs, like the Institute for Clinical and Economic Review already does in the U.S. Other governments have their own drug value assessment agencies, but ICER is not a U.S. government group. Biden made the proposal Sunday night, Bernstein analyst Ronny Gal wrote in a note to clients.